CN106727619A - A kind of Chinese and western medicinal composition of therapeutic radiation enteritis - Google Patents
A kind of Chinese and western medicinal composition of therapeutic radiation enteritis Download PDFInfo
- Publication number
- CN106727619A CN106727619A CN201611236004.5A CN201611236004A CN106727619A CN 106727619 A CN106727619 A CN 106727619A CN 201611236004 A CN201611236004 A CN 201611236004A CN 106727619 A CN106727619 A CN 106727619A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- medicinal composition
- western medicinal
- therapeutic radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 230000005855 radiation Effects 0.000 title claims abstract description 29
- 208000004232 Enteritis Diseases 0.000 title claims abstract description 24
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 24
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 22
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 22
- 239000001527 calcium lactate Substances 0.000 claims abstract description 22
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 22
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims abstract description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000004472 Lysine Substances 0.000 claims abstract description 20
- 229960004343 alendronic acid Drugs 0.000 claims abstract description 20
- 229960005174 ambroxol Drugs 0.000 claims abstract description 20
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 10
- 238000010792 warming Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008367 deionised water Substances 0.000 claims abstract description 8
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 8
- 239000012467 final product Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 238000001959 radiotherapy Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 8
- 230000037396 body weight Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, the Chinese and western medicinal composition is made up of the following raw material according to weight portion：37 parts of Alendronate sodium, 11 19 parts of ambroxol, 5 13 parts of lysine, 15 parts of calcium lactate.Alendronate sodium, ambroxol, calcium lactate are mixed, deionized water is added, 75 77 DEG C, and the 40min of stir process 38 is warming up to, mixture A is obtained；Mixture A is mixed with lysine, the ultrasonically treated 25min at a temperature of 58 DEG C, ultrasonic power is 900W, then stirred to dry at a temperature of 63 DEG C and obtain final product Chinese and western medicinal composition.The present invention has prescription unique, cheap, safe ready, its effect is better than conventional use of Western medicine, Colorectal injury caused during radiotherapy can effectively be cured, cure rate is high, instant effect, have no toxic side effect, non-relapse after healing, preparation process is simple, raw material is simple and easy to get, with short production cycle and low cost, is suitable to industrialized production and large-scale promotion.
Description
Technical field
The present invention relates to pharmaceutical technology field, specifically a kind of Chinese and western medicinal composition of therapeutic radiation enteritis.
Background technology
Radiation enteritis is the intestinal tract complication that pelvic cavity, abdominal cavity, retroperitoneal malignant tumor cause through radiotherapy.Can be respectively
Involve small intestine, colon and rectum, therefore be also called radioactivity rectum, colon, enteritis.The big of dose of radiation is subjected to according to enteron aisle
Small, the time length, the emergency of morbidity, are typically divided into acute and chronic two kinds by radiation sickness.Placed according to ray source again
The difference of internal external position is classified as external exposure radiation sickness and interior irradiation radiation sickness.Updated in early stage protection of intestinal mucosal barrier cells and pressed down
System, with the swelling of metarteriole wall, obturation, causes intestinal wall ischemic, mucosal erosion.Late period intestinal wall causes fibrosis, stenosis of bowel or
Perforation, intraperitoneal formation abscess, fistula road and intestinal adhesion etc..
Radiation colitis not only influences the quality of life of patient, but also can have influence on controlling for tumour because postponing treatment
Therapeutic effect.The main clinical manifestation of radiation colitis is stomachache, diarrhoea, and severe patient occurs has blood in stool and Electrolyte imbalance.
Effective treatment Chinese and western medicinal composition or method are there is no at present, and each medical institutions' majority uses symptomatic treatment, Chinese and Western medicine group used
Compound is also different, and more multiplex is, using Western medicine symptomatic treatment, such as to give the methods such as anti-inflammatory analgetic, fluid infusion antidiarrheal.
The content of the invention
It is an object of the invention to provide a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, to solve above-mentioned background skill
The problem proposed in art.
To achieve the above object, the present invention provides following technical scheme：
A kind of Chinese and western medicinal composition of therapeutic radiation enteritis, is made up of the following raw material according to weight portion：Alendronic acid
Sodium 3-7 parts, ambroxol 11-19 parts, lysine 5-13 parts, calcium lactate 1-5 parts.
As further scheme of the invention：The Chinese and western medicinal composition of the therapeutic radiation enteritis, by following according to weight
Measure the raw material composition of part：Alendronate sodium 4-6 parts, ambroxol 13-17 parts, lysine 7-11 parts, calcium lactate 2-4 parts.
As further scheme of the invention：The Chinese and western medicinal composition of the therapeutic radiation enteritis, by following according to weight
Measure the raw material composition of part：5 parts of Alendronate sodium, 15 parts of ambroxol, 9 parts of lysine, 3 parts of calcium lactate.
A kind of preparation method of the Chinese and western medicinal composition of therapeutic radiation enteritis, comprises the steps of：
1) Alendronate sodium, ambroxol, calcium lactate are mixed, adds the deionized water of 3.1 times of three's mass, be warming up to
75-77 DEG C, and stir process 38-40min at such a temperature, mixture A is obtained；
2) mixture A is mixed with lysine, the ultrasonically treated 25min at a temperature of 58 DEG C, ultrasonic power is 900W, then
Stirred at a temperature of 63 DEG C to dry and obtain final product Chinese and western medicinal composition.
As further scheme of the invention：It is warming up to 76 DEG C, and stir process 39min at such a temperature.
Application of the Chinese and western medicinal composition in therapeutic radiation enteritis Chinese and western medicinal composition is prepared.
Compared with prior art, the beneficial effects of the invention are as follows：
The present invention has prescription unique, cheap, safe ready, and its effect is better than conventional use of Western medicine, Ke Yiyou
Effect cures Colorectal injury caused during radiotherapy, and cure rate is high, and instant effect has no toxic side effect, non-relapse after healing,
Preparation process is simple, raw material is simple and easy to get, with short production cycle and low cost, is suitable to industrialized production and large-scale promotion.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
In the embodiment of the present invention, a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, by the following original according to weight portion
Material composition：3 parts of Alendronate sodium, 11 parts of ambroxol, 5 parts of lysine, 1 part of calcium lactate.
Alendronate sodium, ambroxol, calcium lactate are mixed, the deionized water of 3.1 times of three's mass is added, 75 are warming up to
DEG C, and stir process 38min at such a temperature, mixture A is obtained.Mixture A is mixed with lysine, at a temperature of 58 DEG C
Ultrasonically treated 25min, ultrasonic power is 900W, then is stirred to dry at a temperature of 63 DEG C and obtain final product Chinese and western medicinal composition.
Embodiment 2
In the embodiment of the present invention, a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, by the following original according to weight portion
Material composition：7 parts of Alendronate sodium, 19 parts of ambroxol, 13 parts of lysine, 5 parts of calcium lactate.
Alendronate sodium, ambroxol, calcium lactate are mixed, the deionized water of 3.1 times of three's mass is added, 77 are warming up to
DEG C, and stir process 40min at such a temperature, mixture A is obtained.Mixture A is mixed with lysine, at a temperature of 58 DEG C
Ultrasonically treated 25min, ultrasonic power is 900W, then is stirred to dry at a temperature of 63 DEG C and obtain final product Chinese and western medicinal composition.
Embodiment 3
In the embodiment of the present invention, a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, by the following original according to weight portion
Material composition：4 parts of Alendronate sodium, 13 parts of ambroxol, 7 parts of lysine, 2 parts of calcium lactate.
Alendronate sodium, ambroxol, calcium lactate are mixed, the deionized water of 3.1 times of three's mass is added, 76 are warming up to
DEG C, and stir process 39min at such a temperature, mixture A is obtained.Mixture A is mixed with lysine, at a temperature of 58 DEG C
Ultrasonically treated 25min, ultrasonic power is 900W, then is stirred to dry at a temperature of 63 DEG C and obtain final product Chinese and western medicinal composition.
Embodiment 4
In the embodiment of the present invention, a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, by the following original according to weight portion
Material composition：6 parts of Alendronate sodium, 17 parts of ambroxol, 11 parts of lysine, 4 parts of calcium lactate.
Alendronate sodium, ambroxol, calcium lactate are mixed, the deionized water of 3.1 times of three's mass is added, 76 are warming up to
DEG C, and stir process 39min at such a temperature, mixture A is obtained.Mixture A is mixed with lysine, at a temperature of 58 DEG C
Ultrasonically treated 25min, ultrasonic power is 900W, then is stirred to dry at a temperature of 63 DEG C and obtain final product Chinese and western medicinal composition.
Embodiment 5
In the embodiment of the present invention, a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, by the following original according to weight portion
Material composition：5 parts of Alendronate sodium, 15 parts of ambroxol, 9 parts of lysine, 3 parts of calcium lactate.
Alendronate sodium, ambroxol, calcium lactate are mixed, the deionized water of 3.1 times of three's mass is added, 76 are warming up to
DEG C, and stir process 39min at such a temperature, mixture A is obtained.Mixture A is mixed with lysine, at a temperature of 58 DEG C
Ultrasonically treated 25min, ultrasonic power is 900W, then is stirred to dry at a temperature of 63 DEG C and obtain final product Chinese and western medicinal composition.
Comparative example 1
In addition to calcium lactate is not contained, its formula and preparation process are consistent with embodiment 5.
Comparative example 2
Only contain calcium lactate, its preparation process is consistent with embodiment 5.
Comparative example 3
In addition to without ultrasonic step, remaining constituent content and preparation process are consistent with embodiment 5.
The toxicity test of embodiment 6
1) acute toxicity testing：
Using NIH mouse 60, SPF grades, male and female half and half, 18~22g of body weight carries out acute toxicity test.Mouse is random
It is divided into two groups, every group 30, i.e. control group and administration group, fasting 12 hours before experiment；In prepared by embodiments of the invention 5
Western medicine compound is dissolved in water, (concentration is 6.58g crude drugs/ml, maximum concentration) gavage, and gavage volume is that 5ml/kg is (i.e. single
Secondary dosage is 32.9 crude drugs/kg), control group gives normal saline, is administered 2 times within one day, and delivery time 6 is small
When, Continuous Observation 14 days after administration, and record the toxic reaction and death toll of mouse.Test result indicate that：With control group ratio
Compared with mouse has no notable difference after administration, tests Continuous Observation 14 days, and mouse systemic situation, diet, drinking-water, body weight increase are equal
Normally.32.9 crude drugs of Mouse oral gavage Chinese and western medicinal composition LD50 ＞ of the invention/kg, daily maximum dosage-feeding is 65.8 lifes
Medicine/kg/ days.Chinese medicine clinical application amount of the invention be 1.5g crude drugs/day/people, adult body weight in terms of 60kg, average dosage
For 0.025g crude drugs/kg/ days.By batheroom scale：Mouse (average weight is in terms of 20g) oral administration gavage Chinese and western medicinal composition of the invention
Dosis tolerata be 1316 times of quantity.Therefore Chinese and western medicinal composition acute toxicity of the invention is low, clinical application safety.
2) long term toxicity test：
The Chinese and western medicinal composition of the embodiment of the present invention 5 presses 10.78,20.35 and 33.48g crude drugs/kg continuous uses to mouse
After 15 weeks (1.0ml/100g body weight, daily 2 times) and drug withdrawal 3 weeks, as a result show：Hair of the Chinese and western medicinal composition of the present invention to rat
The indexs such as hair, behavior, stool and urine, body weight, organ weights, blood picture, hepatic and renal function, blood sugar, blood fat have no significant effect, internal organs meat
Eye shows without finding difference change and histological indications, medication 15 weeks and after being discontinued 3 weeks, and each internal organs of rat are without obvious
Change.Chinese and western medicinal composition of the present invention is illustrated to small toxicity after rat long-term prescription, also without abnormal reaction after drug withdrawal, using peace
Entirely.
The clinical test of embodiment 7
1. case selection
The patient 450 of pelvic cavity radiation therapy is selected, 9 groups, respectively every group 50,1 group of embodiment, implementation are randomly divided into
2 groups of example, 3 groups of embodiment, 4 groups of embodiment, 5 groups of embodiment, 1 group of comparative example, 2 groups of comparative example, 3 groups of comparative example, 4 groups of comparative example.
The each group carcinoma of the rectum 25, colon cancer 10, cervical carcinoma 15, ordinary circumstance compares that there was no significant difference.
2. treatment method
All patients take embodiment 1-5 or comparative example respectively by group daily while conventional radiotherapy is received
1-3 Chinese and western medicinal compositions or commercially available treatment Chinese and western medicinal composition once, 10 days as one therapeutic course.The course for the treatment of carries out curative effect and comments after terminating
It is fixed.
3. efficacy evaluation
It is that clinical symptoms and sign disappear to fully recover, and times of defecation is normal, laboratory examination also normal person；Take a turn for the better as symptom is aobvious
Write and mitigate, times of defecation and outward appearance are normal；Head before and after treatment without significant change or to have exacerbation.
4. each group Clinical efficacy comparison：
Each group compares, and the effect of embodiment group is good compared with comparative example group, and each group relatively has significant difference (the results are shown in Table 1).
The present invention is under the interaction of each raw material, and the curative effect of therapeutic radiation enteritis is extremely notable.
Table 1
| Number of cases | Recovery from illness | Take a turn for the better | It is invalid | Total effective rate (%) | |
| 1 group of embodiment | 50 | 30 | 19 | 1 | 98 |
| 2 groups of embodiment | 50 | 32 | 18 | 0 | 100 |
| 3 groups of embodiment | 50 | 40 | 10 | 0 | 100 |
| 4 groups of embodiment | 50 | 41 | 9 | 0 | 100 |
| 5 groups of embodiment | 50 | 45 | 5 | 0 | 100 |
| 1 group of comparative example | 50 | 1 | 21 | 28 | 44 |
| 2 groups of comparative example | 50 | 0 | 2 | 48 | 4 |
| 3 groups of comparative example | 50 | 3 | 20 | 27 | 46 |
| 4 groups of comparative example | 50 | 25 | 20 | 5 | 90 |
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (6)
1. a kind of Chinese and western medicinal composition of therapeutic radiation enteritis, it is characterised in that be made up of the following raw material according to weight portion：
Alendronate sodium 3-7 parts, ambroxol 11-19 parts, lysine 5-13 parts, calcium lactate 1-5 parts.
2. the Chinese and western medicinal composition of therapeutic radiation enteritis according to claim 1, it is characterised in that by following according to weight
Measure the raw material composition of part：Alendronate sodium 4-6 parts, ambroxol 13-17 parts, lysine 7-11 parts, calcium lactate 2-4 parts.
3. the Chinese and western medicinal composition of therapeutic radiation enteritis according to claim 1, it is characterised in that by following according to weight
Measure the raw material composition of part：5 parts of Alendronate sodium, 15 parts of ambroxol, 9 parts of lysine, 3 parts of calcium lactate.
4. the preparation method of the Chinese and western medicinal composition of a kind of therapeutic radiation enteritis as described in claim 1-3 is any, it is special
Levy and be, comprise the steps of：
1）Alendronate sodium, ambroxol, calcium lactate are mixed, the deionized water of 3.1 times of three's mass is added, 75-77 is warming up to
DEG C, and stir process 38-40min at such a temperature, mixture A is obtained；
2）Mixture A is mixed with lysine, the ultrasonically treated 25min at a temperature of 58 DEG C, ultrasonic power is 900W, then 63
Stirred at a temperature of DEG C to dry and obtain final product Chinese and western medicinal composition.
5. the preparation method of the Chinese and western medicinal composition of therapeutic radiation enteritis according to claim 4, it is characterised in that rise
Temperature is to 76 DEG C, and stir process 39min at such a temperature.
6. the Chinese and western medicinal composition as described in claim 1-3 is any is in therapeutic radiation enteritis Chinese and western medicinal composition is prepared
Using.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611236004.5A CN106727619A (en) | 2016-12-28 | 2016-12-28 | A kind of Chinese and western medicinal composition of therapeutic radiation enteritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611236004.5A CN106727619A (en) | 2016-12-28 | 2016-12-28 | A kind of Chinese and western medicinal composition of therapeutic radiation enteritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727619A true CN106727619A (en) | 2017-05-31 |
Family
ID=58924814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611236004.5A Pending CN106727619A (en) | 2016-12-28 | 2016-12-28 | A kind of Chinese and western medicinal composition of therapeutic radiation enteritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727619A (en) |
-
2016
- 2016-12-28 CN CN201611236004.5A patent/CN106727619A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070014821A1 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
| CN101292969B (en) | Application of butyric acid (butanoic acid) in preparing medicaments for treating anorectal diseases | |
| CN104382900A (en) | Compositions and methods for the treatment of radiation proctosigmoitis | |
| CN107714642A (en) | A kind of oral solution of EV71 viruses and CVA16 viral inhibitors and preparation method thereof | |
| Manoguerra et al. | Poisoning with tricyclic antidepressant drugs | |
| CN106420773A (en) | Chinese and western medicinal composition for treating radioactive enteritis, and preparation method and application thereof | |
| CN106511342A (en) | Medicine for treating radiation enteritis and preparation method and application of medicine | |
| CN106727619A (en) | A kind of Chinese and western medicinal composition of therapeutic radiation enteritis | |
| CN109806246A (en) | Propylene glycol is preparing the application in the drug for preventing visible peristalsis visible intestinal peristalsis radiation sickness and radiation enteritis | |
| CN104815014A (en) | Application of polygonum cuspidatum in preparation for medicine for preventing and treating ionization radiation-induced intestinal injuries | |
| CN108125940A (en) | Valeric acid is being prepared for preventing and/or treat the purposes in the drug of neoplasm radiotheraphy secondary reaction | |
| CN106692157A (en) | Medicine for treating radiation enteritis | |
| CN106491602A (en) | A kind of medicine of therapeutic radiation enteritis | |
| CN104095843B (en) | Arctigenin is preparing the application in treating digestive tract ulcer disease medicament | |
| CN106474175A (en) | A kind of medicine of therapeutic radiation enteritis and its preparation method and application | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN110859838A (en) | Application of clopidogrel in preparation of medicine for preventing or treating non-alcoholic fatty liver disease | |
| CN106389439A (en) | Chinese and western medicine composition for curing liver cirrhosis ascites, and preparation method and application thereof | |
| CN106852932A (en) | A kind of medicine for treating cirrhotic ascites | |
| CN1175836C (en) | Medicine for treating pile | |
| Levin et al. | Hepatitis associated with iproniazid (Marsilid®) Report of 3 cases | |
| CN106580955A (en) | Drug for treating hepatitis C virus | |
| CN106580954A (en) | Drug for treating ascites due to cirrhosis and preparation method and application thereof | |
| CN105853399A (en) | Application of patchouli alcohol in preparation of medicine for treating chronic gastritis | |
| CN105362423A (en) | Traditional Chinese medicine preparation for treating phlegm-damp stagnation type stomach cancer, method for preparing traditional Chinese medicine preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |